MNG430
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.373
- INTERFERON_ALPHA_RESPONSE+0.339
- UV_RESPONSE_DN+0.333
- HEME_METABOLISM+0.328
- PROTEIN_SECRETION+0.280
- WNT_BETA_CATENIN_SIGNALING+0.254
- MITOTIC_SPINDLE+0.215
- PEROXISOME+0.191
- INTERFERON_GAMMA_RESPONSE+0.172
- PI3K_AKT_MTOR_SIGNALING+0.167
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.450
- MYC_TARGETS_V2-0.434
- ANGIOGENESIS-0.427
- MTORC1_SIGNALING-0.360
- PANCREAS_BETA_CELLS-0.333
- ESTROGEN_RESPONSE_LATE-0.298
- HYPOXIA-0.294
- CHOLESTEROL_HOMEOSTASIS-0.279
- UV_RESPONSE_UP-0.261
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.241
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.373 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.339 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.333 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.328 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.254 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.215 | Inavolisib | — uncovered |
| PEROXISOME | 0.191 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.172 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.167 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.146 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.141 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.138 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.108 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.099 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.076 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.055 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.012 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.009 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.002 | Inavolisib | — uncovered |